A manufacturer of generic drugs has listed around $1.2 billion of debt on the Bermuda Stock Exchange.

Endo International, whose corporate base is in Ireland, placed the 6 per cent notes, due in February 2025, through Endo Finance Issuers.

Greg Wojciechowski, chief executive officer of the BSX, welcomed the listing which he said was one of largest such issuances the BSX had dealt with.

“We at the BSX have worked hard to continue the maturation of the island’s capital markets,” Mr Wojciechowlski said. “We are the only offshore exchange to be a member of the World Federation of Exchanges.”

That global recognition had helped the BSX become a viable alternative to Luxembourg and Dublin as a listing jurisdiction. And he expected to see more such business coming to the BSX.

A listing on a regulated exchange provided transparency that gave investors comfort, he added.

The BSX has seen few issuances of more than $1 billion. One bigger than the Endo listing was the $1.5 billion issuance by Bermudian special purpose insurer Everglades Re in May 2014 — at the time the biggest catastrophe bond deal in history.

Endo, whose head office is in Dublin, had global sales of $3.7 billion last year and specialises in the production of generic pain medications.